Skip to main content
Publications
Perez-Rodon J, Galve E, Perez-Bocanegra C, Soriano-Sanchez T, Recio-Iglesias J, Domingo-Baldrich E, Alzola-Guevara M, Ferriera-Gonzalez I, Marsal JR, Ribera-Sole A, Gutierrez Garcia-Moreno L, Cruz-Carlos LM, Rivas-Gandara N, Roca-Luque I, Francisco-Pascual J, Evangelista-Masip A, Moya-Mitjans A, Garcia-Dorado D. A risk score to predict the absence of left ventricular reverse remodeling: implications for the timing of ICD implantation in primary prevention. J Cardiol. 2018 May;71(5):505-12. doi: 10.1016/j.jjcc.2017.10.019
Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, Stevens J, Carroll C, Cantrell A, Lobo A, Hoque S. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess. 2016 May;20(39):1-326. doi: 10.3310/hta20390
Olson J, Sharp P, Goatman K, Prescott G, Scotland G, Fleming A, Philip S, Santiago C, Borooah S, Broadbent D, Chong V, Dodson P, Harding S, Leese G, Styles C, Swa K, Wharton H. Improving the economic value of photographic screening for optical coherence tomography-detectable macular oedema: a prospective, multicentre, UK study. Health Technol Assess. 2013 Nov 1;17(51):1-142. doi: 10.3310/hta17510